This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Buyouts Show Sector Not In A Bubble:

Stocks in this article: FRX FURX ACT PFE AZN

NEW YORK (TheStreet) -- Big pharma buyouts have squashed talk of a biotech bubble. This morning, Forest Laboratories  (FRX) announced it would acquire Furiex Pharmaceuticals  (FURX) for about $1.1 billion, or $95 per share. Forest will pay an additional amount, up to $30 per share or $360 million, should Furiex's drug eluxadoline, a treatment for irritable bowel syndrome, receive broad approval.

The merger is the latest in a series of billion-plus biotech deals announced in the past few months. And investors on say it confirms that biotech valuations were never that frothy, as many suggested when the sector sold-off last month.

$FURX Even if milestone achieved later and deal sweetened, still gets done below top tick. Goes to show bios were priced for perfection. - JLL IV (@TXplunger) Apr. 28 at 08:42 AM

The Furiex acquisition comes a few months after Actavis  (ACT) announced it would acquire Forest Laboratories for $25 billion in equity and cash. At the time of the announcement, Actavis said that the combined company would have annual revenues of over $15 billion in 2015. Forest made it clear that its "blockbuster" gastrointestinal drugs were a major reason for the deal.

$ACT eats $FRX who eats $FURX #biotechfoodchain - Kevin F. (@Katsu) Apr. 28 at 07:28 AM

The Furiex purchase also comes in the wake of Pfizer's  (PFE) pursuit of AstraZeneca  (AZN). Pfizer management said in a press release early this morning that it attempted to acquire AstraZeneca for $76.62-per-share in January. AstraZeneca declined the offer, saying it significantly undervalued its drug pipeline. Pfizer contacted AstraZeneca management on April 26 seeking to renew merger discussions.

Investors on StockTwits say the Furiex deal is better for shareholders than AstraZeneca. Furiex stock climbed more than 30% in the pre-market to $104.50 per share. Though it pulled back slightly by 9:40 a.m. AstraZeneca climbed more than 15% this morning to top $79-per-share.

$FURX is the early winner of Merger Monday ..... $azn is a distant second, but first in terms of dollar value. - BBolan1 (@bbolan1) Apr. 28 at 09:14 AM

Forest Labs and Actavis also edged higher on the Furiex deal news. Furiex's eluxadoline is a major reason for the enthusiasm over the deal. In February, Furiex announced the results of Phase III clinical trials of eluxadoline in which the drug helped lessen abdominal pain in IBS sufferers and controlled diarrhea. "The acquisition of Furiex builds on our growing position in gastroenterology and helps to create a leading GI company within Forest," said Brent Saunders, Forest Laboratories CEO, in a statement. "With eluxadoline, we expect to have one of the broadest product offerings for the $38 billion GI disease market."

At the time of publication the author had no position in any of the stocks mentioned.

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,085.46 +55.25 0.31%
S&P 500 2,091.24 +9.36 0.45%
NASDAQ 4,808.4920 +35.02 0.73%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs